GEMNabP

DRUG2 trials

Sponsors

Incyte Corporation

Conditions

Solid Tumors

Phase 1

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

RecruitingNCT06179160

Incyte CorporationSolid Tumors

Start: 2024-01-04End: 2027-01-01Target: 710Updated: 2026-05-04

A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Active, not recruitingNCT06818812

Incyte CorporationSolid Tumors

Start: 2025-03-27End: 2027-03-27Updated: 2026-03-23

Related Papers

Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced/metastatic pancreatic duct adenocarcinoma (PDAC).

Journal of Clinical Oncology2026-01-10